A Phase 3 Prospective, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy with MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants

July 11, 2018
https://clinicaltrials.gov/ct2/show/NCT03363945
Transplant
Principal Investigator: Anita K Patel, MD
transplant, kidney transplant, transplant institute, kidney, nephrology, medeor, tolerance, living donor, donor, living, perfect match
Accepting Participants